Skip to Content

'
Aung Naing, MD, FACP

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

  • Phase 1 studies
  • Drug development

Office Address

The University of Texas MD Anderson Cancer Center
Department of Investigational Cancer Therapeutics
1515 Holcombe Blvd.
Unit Number: 455
Houston, TX 77030
Room Number: FC8.2026
Phone: 713-563-0181
Fax: 713-792-5576
Email: anaing@mdanderson.org

Education & Training

Degree-Granting Education

1997 Hacettepe University, Faculty of Medicine, Ankara, Turkey, MD, Doctor of Medicine

Postgraduate Training

8/2005-7/2006 Clinical Fellowship, Bone Marrow Transplant, City of Hope Cancer Center, Duarte, CA
7/2002-6/2005 Clinical Fellowship, Hematology, H. Lee Moffitt Cancer Center & Research Institute (University of South Florida, College of Medicine), Tampa, FL
7/2002-6/2005 Clinical Fellowship, Medical Oncology, H. Lee Moffitt Cancer Center & Research Institute (University of South Florida, College of Medicine), Tampa, FL
7/1999-6/2002 Clinical Residency, Internal Medicine, State University of New York, Upstate Medical University, Syracuse, NY

Board Certifications

11/2007 The American Board of Internal Medicine in Medical Oncology
10/2006 The American Board of Internal Medicine in Hematology
8/2002 The American Board of Internal Medicine in Internal Medicine

Experience/Service

Institutional Committee Activities

Member, Clinical Research Committee, 9/2009-2012
Member, Study Section Review Committee for Clinical Translational Population-Based Research Projects, 9/2008-present
Designated Alternate Member for Investigational Cancer Therapeutics, Credentials Committee of Medical Staff, 7/2008-present

Honors and Awards

2011-2012 Voted one of The Best Doctors in America
2008-present Fellow of The American College of Physicians, American College of Physicians
2006 The ASCO Merit Award 2006, American Society of Clinical Oncology
2003 Scholarship to attend 10th National Symposium on Basic Aspects of Vaccines, Walter Reed Army Institute of Research, Silver Spring, MD

Selected Publications

Peer-Reviewed Original Research Articles
1. Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R. Phase 1 clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol 66(6):1087-93, 11/2010. e-Pub 3/2010. PMID: 20204368.

Abstracts
1. Naing A, Cheng F, Wang H, Horna P, Suarez I, Brayer J, List AF, Sotomayor EM. Lenalidomide (CC5013), a Thalidomide Analogue with Immunomodulatory Properties, Significantly Enhances the Function of Antigen-Presenting Cells (APCs). Joint Cancer Conference Oncology Young Investigators Forum, 1/2005.
2. Wang H, Cheng F, Naing A, Atadja AP, Bhalla K, Sotomayor EM. Histone Deacetylase(HDAC) Inhibitor LAQ842 is a Potent Inducer of Inflammatory Antigen-Presenting Cells (APCs) that Effectively Prime Naïve Antigen-Specific T-Cells and Restore the Responsiveness of Anergic T Cells from Tumor Bearing Hosts. American Society of Hematology (#Poster 124-I), 2003.

Last updated: 3/8/2013